Piper Jaffray Cuts Bristol-Myers (BMY) PT, Raises Merck's (MRK) Following BMY's CM-026 Failure
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Piper Jaffray analyst Richard Purkiss lowered his price target on Neutral-rated Bristol-Myers Squibb Co. (NYSE: BMY) to $65.00 (from $69.00) following news Friday that its CheckMate-026 (CM-026) trial of Opdivo missed its primary endpoint in the treatment of PD-L1+ expressors (>5% PD-L1+,~55-60% of patients) in first-line NSCLC (1L NSCLC). This failure was in stark contrast to Merck’s Keytruda which met the primary and secondary endpoint of Progression Free Survival (PFS) and Overall Survival (OS) in 1L NSCLC in PD-L1 high expressors (>50% PD-L1+,~25-30% of patients).
Meanwhile, the firm raised its price target on Neutral-rated Merck (NYSE: MRK) to $62.00 (from $58.00) on the same news.
Shares of Bristol-Myers Squibb Co. closed at $63.28 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY): Selloff Overdone - Jefferies
- UPDATE: Seaport Global Securities Upgrades Columbus McKinnon (CMCO) to Buy
- Hilliard Lyons Upgrades BB&T Capital (BBT) to Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesPiper Jaffray
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!